Correction to: Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations ; volume:35 ; number:7 ; day:9 ; month:6 ; year:2018 ; pages:966 ; date:7.2018
Advances in therapy ; 35, Heft 7 (9.6.2018), 966, 7.2018
- Urheber
-
Blonde, Lawrence
- Beteiligte Personen und Organisationen
-
Dipp, Susana
Cadena, Daniel
SpringerLink (Online service)
- DOI
-
10.1007/s12325-018-0729-6
- URN
-
urn:nbn:de:101:1-2018092120441900963395
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Blonde, Lawrence
- Dipp, Susana
- Cadena, Daniel
- SpringerLink (Online service)
Ähnliche Objekte (12)
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
The effects of yam gruel on lowering fasted blood glucose in T2DM rats
Pharmacogenetics of novel glucose-lowering drugs
SGLT2i: beyond the glucose-lowering effect
The pathophysiology of glucose intolerance in newly diagnosed, untreated T2DM
Diabetes, bone and glucose-lowering agents: basic biology
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Cardiovascular outcome trials of glucose-lowering medications: an update
Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
Diabetes, glucose control, glucose lowering medications, and cancer risk: A 10-year population-based historical cohort
Case-Based Optimization
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
The effects of yam gruel on lowering fasted blood glucose in T2DM rats
Pharmacogenetics of novel glucose-lowering drugs
SGLT2i: beyond the glucose-lowering effect
The pathophysiology of glucose intolerance in newly diagnosed, untreated T2DM
Diabetes, bone and glucose-lowering agents: basic biology
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Cardiovascular outcome trials of glucose-lowering medications: an update
Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
Diabetes, glucose control, glucose lowering medications, and cancer risk: A 10-year population-based historical cohort
Case-Based Optimization
Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations
The effects of yam gruel on lowering fasted blood glucose in T2DM rats
Pharmacogenetics of novel glucose-lowering drugs
SGLT2i: beyond the glucose-lowering effect
The pathophysiology of glucose intolerance in newly diagnosed, untreated T2DM
Diabetes, bone and glucose-lowering agents: basic biology
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Cardiovascular outcome trials of glucose-lowering medications: an update
Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
Diabetes, glucose control, glucose lowering medications, and cancer risk: A 10-year population-based historical cohort